Global Market Expansion Insightec's Exablate Neuro MR-guided focused ultrasound treats essential tremor and Parkinson's disease, with a global footprint supported by offices in Haifa, Miami, Dallas, Shanghai and Tokyo. France has published national reimbursement for unilateral MR-guided focused ultrasound for medication-refractory essential tremor, signaling payer readiness and creating a near-term market opportunity with European hospitals and neurology centers. Leverage this momentum by engaging regional health systems, distributors, and payer strategies to accelerate adoption.

Regulatory Milestones Health Canada issued a Medical Device License for Exablate Prime, enabling entry to the Canadian market. This regulatory validation complements European reimbursement progress and supports a multi-region sales plan. Align regulatory, clinical, and reimbursement teams to pursue additional markets and smooth market entry for new regions.

Partnership & Pipeline Strategic collaborations with AIIMS Delhi and Tremor UK demonstrate a broad ecosystem for clinical adoption and training. The Lotus Neuro spin-out pursuing ultrasound-based therapy for brain cancer indicates potential cross-therapy opportunities in oncology and neurology. Target hospitals, academic centers, and oncology and neurology departments for joint trials and education programs.

Market Leadership Insightec is a leading MR-guided focused ultrasound provider with recognized clinical and industry accolades for Exablate Neuro. This credibility supports hospital procurement discussions and payer negotiations by emphasizing outcomes, safety, and patient impact.

Funding & Capacity Strong equity backing from global investors underpins ongoing expansion of sales, clinical programs, and service capabilities. This financial momentum enables scaling in high-potential markets and investments in training, installation, and ongoing support for large hospital networks.